• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)

The Blood Industry

  • Publication Date:March 2011
  • Publisher:BCC Research
  • Product Type: Report
  • Pages:197

The Blood Industry

REPORT HIGHLIGHTS

  • The global blood market includes products used for collecting, typing, processing, and transfusing of blood and the sale of blood therapeutics. This market was worth $30 billion in 2010 and is forecast to increase at an 8.4% compound annual growth rate (CAGR) to reach $45 billion in 2015.
  • Blood therapeutic products, including immunoglobulins, coagulation factors, albumin, fibrin sealants, and antithrombin products, are projected to grow at a compound annual growth rate (CAGR) of 10.8% over the 5-year forecast period. This sector was valued at nearly $16 billion in 2010 and is expected to reach $26 billion in 2015.
  • Sales for blood processing, collection, and typing/testing reached $14 billion in 2010. This market is forecast to grow at a 5.5% compound annual growth rate (CAGR) to reach more than $18 billion in 2015.

REPORT SCOPE

INTRODUCTION

REASONS FOR DOING THE STUDY

A safe and adequate blood supply is essential to the practice of modern medicine. Ensuring adequate supplies of trustworthy blood and derivative products has lead nations and companies to create a multibillion-dollar business that reaches around the globe.

The global blood industry encompasses the collection, typing, testing, and processing of blood and the creation of blood derivatives to help individuals with varying blood problems. The purpose of this study is to detail advances in these areas and their impact on the blood industry.

During the past 10 years, since BCC first looked at this market, mergers and acquisitions have created an industry dominated by less than 10 major companies. This consolidation and advances in technology have allowed industry participants to obtain more red blood cells from fewer donors. Technological advances have also allowed for greater economies and increased safety in the blood supply.

STUDY GOALS AND OBJECTIVES

With its broad scope and in-depth analyses, this study will be a valuable resource to anyone involved with or interested in the blood industry. This study will provide information on:

  • Structure and current market size of the blood industry, with forecasts through 2015
  • Analysis and projections of various segments of the industry such as collection, typing, testing, and blood therapeutics
  • Blood usage patterns and trends
  • Government and regulatory controls
  • Impact of diseases on the blood industry
  • Major players and their relative market shares and market potential
  • Current product lines and examination of newly emerging products and technologies
  • State of the international markets for various blood and blood-related products
  • Newly issued patents relating to blood therapeutics, processing, screening, and collection technologies.

The study will prove valuable to a variety of readers, including industry executives, managers and planners, researchers, industry analysts, and investors. The projections, forecasts, and trend analyses found in this report provide readers with the necessary data and information for careful decision- making.

SCOPE OF REPORT

This report offers global and U.S. projections, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of blood and plasma collection, blood and plasma processing, blood therapeutic products, plasma therapeutic products, and emerging trends and products.

The arrangement of this report offers an overview of the key elements in the blood collection and processing businesses: blood typing techniques and markets, and plasma fractionation. International markets are discussed, and information is provided on industry structure and the regulatory environment outside the U.S.

Profiles of more than 30 leading companies involved with blood collection, processing, and therapeutics are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, annual reports and SEC reports, the American Red Cross (ARC), the American Association of Blood Banks (AABB), the Plasma Protein Therapeutics Association (PPTA), the National Institutes of Health (NIH), the Centers for Disease Control (CDC), other government agencies, and journal articles. Secondary sources include literature searches, product literature, and press releases.

When precise information was not available, a consensus was made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr has worked with the publishing arms of for-profit and nonprofit organizations for more than 30 years. She specializes in marketing reports on the medical industry, and has contributed several reports on the medical industry for BCC.

  • CHAPTER ONE: INTRODUCTION
    • REASONS FOR DOING THE STUDY
    • STUDY GOAL AND OBJECTIVES
    • SCOPE OF REPORT
    • METHODOLOGIES AND INFORMATION SOURCES
    • ANALYST CREDENTIALS
    • RELATED BCC REPORTS
    • BCC ONLINE SERVICES
    • DISCLAIMER
  • CHAPTER TWO: SUMMARY
    • MAJOR FINDINGS
    • SUMMARY TABLE GLOBAL BLOOD COLLECTION, PROCESSING, AND THERAPEUTICS MARKET, THROUGH 2015 ($ MILLIONS)
    • SUMMARY FIGURE GLOBAL BLOOD MARKET, BY REGION, 2010 AND 2015 (%)
    • SUMMARY FIGURE (CONTINUED)
  • CHAPTER THREE: OVERVIEW
    • HISTORY OF THE BLOOD INDUSTRY
    • CONSOLIDATION IN THE INDUSTRY
    • DYNAMICS OF BLOOD DONATION
    • BLOOD COLLECTION AND PROCESSING MARKET STRUCTURE
    • AND SIZE
    • BLOOD AND ITS COMPONENTS
    • PLASMA
    • Uses for Plasma Proteins
    • Immunoglobulin Products
    • CELLULAR ELEMENTS
    • Red Blood Cells
    • White Blood Cells
    • Platelets
    • TRANSFUSION-ASSOCIATED RISKS
    • DISEASES CONTRACTED FROM BLOOD TRANSFUSION AND RELATED IDENTIFICATION TESTING
    • HIV/AIDS
    • Hepatitis A
    • Worldwide Incidences of Hepatitis A
    • Hepatitis B (HBV)
    • Hepatitis C
    • Hepatitis D
    • Hepatitis E
    • Human T-Cell Lymphotropic Virus (HTLV-I, II)
    • Cytomegalovirus
    • "Mad Cow Disease"/Creutzfeldt-Jakob Disease (CJD)
    • Syphilis
    • Chagas Disease
    • CREATING A VIRUS-FREE BLOOD SUPPLY
    • CERUS CORP.
    • COST OF A VIRUS-FREE BLOOD SUPPLY
    • PLASMA TREATMENTS TO INACTIVATE VIRUSES
    • Trinitrobutyl Phosphate and Sodium Cholate
    • Methylene Blue-Treated Plasma
    • Amatosalen HCL-Treated Plasma
    • NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS
    • BLOOD/PLASMA COMPONENT RISKS
  • CHAPTER FOUR: BLOOD COLLECTION, TYPING, AND PROCESSING
    • BLOOD COLLECTION
    • METHODS FOR COLLECTING BLOOD
    • MANUAL COLLECTION
    • AUTOMATED COLLECTION
    • Plasmapheresis
    • Plateletpheresis
    • Leukopheresis
    • Red Blood Cell Apheresis
    • BLOOD SALVAGE EQUIPMENT
    • BLOOD BAGS
    • BLOOD FILTERS
    • TRANSFUSION SETS, ACCESSORIES
    • OTHER EQUIPMENT
    • MARKET DRIVERS IN BLOOD COLLECTION
    • U.S. BLOOD COLLECTION ORGANIZATIONS
    • FOR-PROFIT BLOOD COLLECTION CONTROVERSY
    • NONPROFIT BLOOD COLLECTION IN THE U.S
    • American Red Cross (ARC)
    • Community Blood Banks
    • Hospitals
    • Other Blood Collection Sites
    • U.S. BLOOD DONATION DEMOGRAPHICS
    • DONOR RECRUITMENT AND REGULATIONS
    • BLOOD SCREENING AND EVALUATION
    • BLOOD COLLECTION EFFORTS THROUGHOUT THE WORLD
    • SOUTH AMERICA/CENTRAL AMERICA
    • ASIA
    • PACIFIC REGION
    • AFRICA
    • CANADA
    • EUROPE
    • United Kingdom
    • France
    • GLOBAL NATURE OF THE PLASMA INDUSTRY
    • PLASMA DONORS
    • COMMERCIAL NATURE OF PLASMAPHERESIS
    • PLASMA COLLECTION CENTERS IN THE U.S
    • National Donor Referral Registry
    • PLASMA FRACTIONATORS
    • DISTRIBUTORS/BROKERS
    • BLOOD TYPING
    • METHODS OF TYPING
    • Slide/Tile Testing
    • Tube Testing
    • Microplate Testing Methods
    • AUTOMATED BLOOD TYPING AND SCREENING METHODS
    • Immucor
    • Ortho-Clinical Diagnostics
    • Abbott
    • BLOOD TRANSFUSION TESTING
    • MANUAL CROSSMATCH TECHNIQUES
    • Major Crossmatch
    • Minor Crossmatch
    • Antibody Screening
    • Coombs Test
    • BLOOD TESTING
    • BLOOD PROCESSING
    • PREPARATION AND USE OF THE COMPONENTS
    • Red Blood Cells
    • Platelets
    • MARKET PARTICIPANTS
    • Haemonetics
    • PCS2
    • TCD Total Containment Unit
    • MCS+ 8150 System
    • Cell Saver System
    • OrthoPAT System
    • ACP 215 System
    • Fenwal
    • Autopheresis-C
    • Alyx Component Collection System
    • CS-3000 Plus Blood Cell Separator
    • Amicus Separator
    • Gambro BCT
    • Trima Accel Collection System
    • COBE Spectra Apheresis System
    • The Elutra Cell Separation System
    • GLOBAL BLOOD MANAGEMENT ISSUES
    • AVAILABILITY
    • BLOODLESS SURGERY
    • FEWER OPEN SURGICAL PROCEDURES
    • SAFETY ISSUES/RISK MANAGEMENT
    • Improved Donor Screening
    • Better Viral Testing
    • Encouraging Repeat Donors
    • Improving Viral Inactivation Processes
    • Selective Use of Blood Derivative Products
  • CHAPTER FIVE: BLOOD THERAPEUTICS
    • WHOLE BLOOD
    • PACKED RED BLOOD CELLS
    • PLATELETS
    • LEUKOCYTES
    • FRESH FROZEN PLASMA
    • SELECTED USES OF FFP
    • CRYOPRECIPITATE
    • WASHED CELLS
    • DEGLYCEROLIZED CELLS
    • OTHER BLOOD COMPONENTS
    • GRANULOCYTES
    • GAMMA-IRRADIATED BLOOD
    • DISTRIBUTION OF COLLECTED BLOOD
    • PLASMA AND PLASMA-DERIVED PRODUCTS
    • GLOBAL PLASMA COLLECTION
    • PLASMA MARKET SIZE
    • COAGULATION FACTORS
    • IMMUNE SERUM GLOBULIN/INTRAMUSCULAR IMMUNE GLOBULINS (IMIG)/INTRAVENOUS IMMUNE GLOBULIN (IVIG)
    • Market Shortages of IVIG
    • FACTOR VIII
    • FACTOR IX AND FACTOR IX COMPLEX
    • FACTOR VIIA
    • FIBRIN/THROMBIN
    • THERAPEUTIC APHERESIS
    • CLOTTING FACTORS
    • Hemophilia
    • CLOTTING FACTOR MARKET DEMAND AND MARKET SIZE
    • Factor VIII
    • Advate
    • Helixate FS
    • Kogenate FS
    • Recombinate
    • ReFacto
    • GLOBAL SHARE IN FACTOR VIII MARKET
    • Factor IX
    • Factor VIIa
    • ALBUMIN
    • RECOMBINANT HUMAN ALBUMIN
    • Recombinant Human Albumin Market
    • ALBUMIN MARKET DYNAMICS
    • ALBUMIN AND PPF MARKET SIZE
    • PROTHROMBIN COMPLEX CONCENTRATE
    • FIBRIN SEALANTS AND THROMBIN
    • FIBRIN-BASED WOUND CLOSURE PRODUCT MARKET
    • Cyanoacrylate
    • ANTITHROMBIN TREATMENTS
    • TREATMENTS FOR HD
    • Plasma Antithrombin
    • Recombinant Human Antithrombin (rhAT)
    • Talecris Biotherapeutics
    • GTC Biotherapeutics
    • GlaxoSmithKline (Arixtra)
    • GLOBAL MARKET FOR ANTITHROMBIN
    • IMMUNOGLOBULINS
    • POLYVALENT IMMUNOGLOBULINS
    • The Projected Global IVIG Therapy Market
    • HYPERIMMUNE IMMUNOGLOBULINS
    • GLOBAL MARKET FOR HYPERIMMUNOGLOBULINS
    • Respiratory Syncytial Virus (RSV)
    • Alpha-1-Proteinase Inhibitor
    • Rho(D)
    • Hepatitis B Immune Globulin
    • CMV Immunoglobulin
    • Tetanus Immunoglobulin
    • Rabies Immunoglobulin
    • Varicella Immunoglobulin
    • Vaccinia Immune Globulin Intravenous (VIG)
  • CHAPTER SIX: BLOOD INDUSTRY REGULATION
    • REGULATION OF THE U.S. BLOOD BUSINESS
    • STATUTORY AUTHORITY OF THE FDA
    • Center for Biologics Evaluation and Research
    • Office of Regulatory Affairs (ORA)
    • Office of Biologics, the Division of Blood and Blood Products
    • MAJOR REGULATIONS AND POLICIES FOR THE U.S. BLOOD SUPPLY
    • THE CLINICAL LABORATORY IMPROVEMENT ACT OF 1988 (CLIA)
    • THE FDA APPROACH TO BLOOD REGULATION
    • TEAM BIOLOGICS
    • REGULATION IMPLEMENTATION
    • OTHER U.S. ORGANIZATIONS INVOLVED IN BLOOD REGULATION
    • National Heart, Lung, and Blood Institute (NHLBI)
    • Blood Disease and Resources Program
    • Occupational Safety and Health Administration (OSHA)
    • Centers for Medicare and Medicaid Services (CMS)
    • State Regulatory Agencies
    • VOLUNTARY REGULATION BY PROFESSIONAL AND TRADE ASSOCIATIONS
    • American Association of Blood Banks (AABB)
    • National Donor Deferral Registry (NDDR)
    • Quality Plasma Program
    • America's Blood Centers (ABC)
    • Plasma Products Therapeutics Association (PPTA
    • EUROPEAN UNION (EU) REGULATIONS
    • THE INTERNATIONAL SOCIETY FOR BLOOD TRANSFUSION (ISBT) 128
    • REGULATION IN JAPAN
    • REGULATION IN CHINA
    • THE FUTURE OF GLOBAL BLOOD REGULATIONS
  • CHAPTER SEVEN: BLOOD PRODUCTS TECHNOLOGY
    • FRACTIONATION METHODS
    • COHN METHOD
    • ADVANCED FRACTIONATION METHODS
    • Chromatography Methods
    • AMPLIFICATION METHODS
    • POLYMERASE CHAIN REACTION
    • NUCLEI AMPLIFICATION TECHNOLOGY
    • IMMUNOASSAY METHODS
    • ENZYME IMMUNOASSAY
    • Basic EIA
    • Second Antibody Precipitation Method
    • Double Antibody Sandwich Method
    • Reverse Sandwich Method
    • Reverse Sandwich Inhibition Method
    • AGGLUTINATION
    • CHEMILUMINESCENCE (CHLIA)
    • ENDOTOXIN TESTING
  • CHAPTER EIGHT: BLOOD RESEARCH AND DEVELOPMENT
    • JEROME H. HOLLAND LABORATORY (ARC)
    • NATIONAL BLOOD FOUNDATION (NBF)
    • CENTER FOR BLOOD RESEARCH (CBR)
    • STEM CELL RESEARCH AT THE CBR
    • FDA BLOOD RESEARCH PRODUCTS
    • STEM CELL DEVELOPMENTS OUTSIDE THE U.S
    • NOVEL BIOENGINEERING TECHNOLOGIES
    • RESEARCH ON ALZHEIMER'S AND CIRRHOSIS OF THE LIVER
    • CURRENT RESEARCH ON BLOOD SUBSTITUTES
    • EMERGING PLATELET TREATMENTS
    • RED BLOOD CELLS
    • THE VETERINARY BLOOD MARKET
  • CHAPTER NINE: PATENTS
  • CHAPTER TEN: COMPANY PROFILES
    • ABBOTT LABORATORIES
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • ALPHA THERAPEUTICS CORP. (SEE GRIFOLS)
    • AMERICA'S BLOOD CENTERS
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • AMERICAN ASSOCIATION OF BLOOD BANKS (AABB)
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • AMERICAN RED CROSS
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BAXTER INTERNATIONAL, INC.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BECKMAN COULTER
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BECTON DICKINSON AND COMPANY
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BIO PRODUCTS LABORATORIES
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BIO-RAD LABORATORIES, INC.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • BIOTEST AG
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • CARIDIANBCT INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • CERUS CORP
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • CHIRON CORP. (SEE NOVARTIS DIAGNOSTICS)
    • CSL BEHRING
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • DAXOR CORP
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • DIAGAST
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • FENWAL BLOOD TECHNOLOGIES, INC.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • FRESENIUS KABI AG
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • GEN-PROBE, INC.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • GRIFOLS BIOLOGICALS, INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • HAEMONETICS, INC.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • Cell Saver System
    • OrthoPAT System
    • ACP 215 System
    • HEMAGEN DIAGNOSTICS, INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • HEMOCUE AB
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • IMMUCOR, INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • KAWASUMI LABORATORIES, INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • LUMINEX CORPORATION
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • MACOPHARMA USA (FORMERLY UNITED PHARMA)
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • NOVARTIS DIAGNOSTICS
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
    • NOVO NORDISK
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • OCTAPHARMA
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • OLYMPUS AMERICA, INC. (SEE BECKMAN COULTER)
    • ONE LAMBDA, INC
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • ORTHO-CLINICAL DIAGNOSTICS
    • FINANCIALS
    • PRODUCTS
    • PALL CORP.
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • PFIZER
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • TALECRIS BIOTHERAPEUTICS
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • TERUMO MEDICAL CORP
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
    • THERMOGENESIS CORP
    • BUSINESS OVERVIEW
    • FINANCIALS
    • PRODUCTS
+44 20 8816 8548

Ask a question about The Blood Industry

Enter the characters you see in the picture below
Captcha